Use este identificador para citar ou linkar para este item:
http://hdl.handle.net/1843/47164| Tipo: | Artigo de Periódico |
| Título: | Lamotrigine as a mood stabilizer: insights from the pre-clinical evidence |
| Autor(es): | Aline Silva de Miranda Amanda Silva de Miranda Antonio Lucio Teixeira Junior |
| Resumo: | Introduction: Lamotrigine (LTG) is a well-established anticonvulsant that is also approved for the prevention of mood relapses in bipolar disorder. However, the mechanisms underlying LTG mood stabilizing effects remain unclear. Areas covered: Herein, the pre-clinical evidence concerning LTG’s’ mode of action in depression and mania is reviewed. Bottlenecks and future perspectives for this expanding and promising field are also discussed. Pre-clinical studies have indicated that neurotransmitter systems, especially serotoninergic, noradrenergic and glutamatergic, as well as non-neurotransmitter pathways such as inflammation and oxidative processes might play a role in LTG’s antidepressant effects. The mechanisms underlying LTG’s anti-manic properties remain to be fully explored, but the available pre-clinical evidence points out to the role of glutamatergic neurotransmission, possibly through AMPA-receptors. Expert opinion: A major limitation of current pre-clinical investigations is that there are no experimental models that recapitulate the complexity of bipolar disorder. Significant methodological differences concerning time and dose of LTG treatment, administration route, animal strains, and behavioral paradigms also hamper the reproducibility of the findings, leading to contradictory conclusions. Moreover, the role of other mechanisms (e.g. inositol phosphate and GSK3β pathways) implicated in the mode of action of different mood-stabilizers must also be consolidated with LTG. |
| Assunto: | Transtorno bipolar Depressão mental Dopamina Glutamato monossódico Serotonina Distúrbios cognitivos Modelos animais |
| Idioma: | eng |
| País: | Brasil |
| Editor: | Universidade Federal de Minas Gerais |
| Sigla da Instituição: | UFMG |
| Departamento: | ICB - DEPARTAMENTO DE MORFOLOGIA ICX - DEPARTAMENTO DE QUÍMICA MED - DEPARTAMENTO DE CLÍNICA MÉDICA |
| Tipo de Acesso: | Acesso Restrito |
| Identificador DOI: | https://doi.org/10.1080/17460441.2019.1553951 |
| URI: | http://hdl.handle.net/1843/47164 |
| Data do documento: | 2019 |
| metadata.dc.url.externa: | https://www.tandfonline.com/doi/abs/10.1080/17460441.2019.1553951?journalCode=iedc20 |
| metadata.dc.relation.ispartof: | Expert Opinion on Drug Discovery |
| Aparece nas coleções: | Artigo de Periódico |
Arquivos associados a este item:
Não existem arquivos associados a este item.
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.